The DOI matches its Crossref record; 431 of the 431 references it cites were found in a registry or an index.
Inhibition and induction of CYP enzymes in humans: an update
Open accessAbstract
The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies and toxic compounds in the environment. The inhibition and induction of CYPs are major mechanisms causing pharmacokinetic drug–drug interactions. This review presents a comprehensive update on the inhibitors and inducers of the specific CYP enzymes in humans. The focus is on the more recent human in vitro and in vivo findings since the publication of our previous review on this topic in 2008. In addition to the general presentation of inhibitory drugs and inducers of human CYP enzymes by drugs, herbal remedies, and toxic compounds, an in-depth view on tyrosine-kinase inhibitors and antiretroviral HIV medications as victims and perpetrators of drug–drug interactions is provided as examples of the current trends in the field. Also, a concise overview of the mechanisms of CYP induction is presented to aid the understanding of the induction phenomena.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 431
Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib
Amaya, G. M., Durandis, R., Bourgeois, D. S., Perkins, J. A., Abouda, A. A., Wines, K. J., Mohamud, M., Starks, S. A., Daniels, R. N., & Jackson, K. D. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00005 · Cited by 95
Kanamitsu, S.-I., Ito, K., Green, C. E., Tyson, C. A., Shimada, N., & Sugiyama, Y. (2000) · Pharmaceutical Research · doi:10.1023/a:1007572803027 · Cited by 94
Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes
Glaeser, H., Drescher, S., Eichelbaum, M. F., & Fromm, M. F. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02265.x · Cited by 94
Mildvan, D., Yarrish, R. L., Marshak, A., Hutman, H. W., McDonough, M., Lamson, M. J., & Robinson, P. A. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200204150-00007 · Cited by 94
Artemisinin induces omeprazole metabolism in human beings*
Svensson, U. S. H., Ashton, M., Hai, T. N., Bertilsson, L., Huong, D. X., Hướng, N. V., Niêu, N. T., Sy, N. D., Lykkesfeldt, J., & Công, L. D. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90149-7 · Cited by 94
Gallant, J. E., Thompson, M., DeJesus, E., Voskuhl, G. W., Wei, X., Zhang, H., White, K., Cheng, A., Quirk, E. K., & Martin, H. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001306 · Cited by 94
Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling
Min, J. S., & Bae, S. K. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0976-0 · Cited by 94
Yu, J., Petrie, I. D., Levy, R. H., & Ragueneau, I. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.084905 · Cited by 93
Raaska, K., & Neuvonen, P. J. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280000192 · Cited by 91
Small-molecule modulators of PXR and CAR
Chai, S. C., Cherian, M. T., Wang, Y., & Chen, T. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.02.013 · Cited by 91
Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes
Yasui‐Furukori, N., Takahata, T., Nakagami, T., Yoshiya, G., Inoue, Y., Kaneko, S., & Tateishi, T. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02047.x · Cited by 90
Millonig, G., Wang, Y., Homann, N., Bernhardt, F., Qin, H., Mueller, S., Bartsch, H., & Seitz, H. K. (2010) · International Journal of Cancer · doi:10.1002/ijc.25604 · Cited by 90
Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
Dutreix, C., Munarini, F., Lorenzo, S., Roesel, J. L., & Wang, Y. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2287-6 · Cited by 90
Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery
Lolodi, O., Wang, Y., Wright, W. C., & Chen, T. (2017) · Current Drug Metabolism · doi:10.2174/1389200218666170531112038 · Cited by 90
Effect of rifampicin on the pharmacokinetics of pioglitazone
Jaakkola, T., Backman, J. T., Neuvonen, M., Laitila, J., & Neuvonen, P. J. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02515.x · Cited by 89
Perucca, E., Grimaldi, R., Frigo, G. M., Sardi, A., M�nig, H., & Ohnhaus, E. E. (1988) · European Journal of Clinical Pharmacology · doi:10.1007/bf00615223 · Cited by 89
Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway
Wang, K., Chen, S., Xie, W., & Wan, Y. Y. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.02.030 · Cited by 89
Specific and Dose–Dependent Enzyme Induction by Omeprazole in Human Beings
Rost, K. L., Brösicke, H., Heinemeyer, G., & Roots, I. (1994) · Hepatology · doi:10.1002/hep.1840200516 · Cited by 89
CLINICAL IMPLICATIONS OF ENZYME INDUCTION
Breckenridge, A., & Orme, M. (1971) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1971.tb46919.x · Cited by 88
A review of the molecular design and biological activities of RXR agonists
de Almeida, N. R., & Conda‐Sheridan, M. (2019) · Medicinal Research Reviews · doi:10.1002/med.21578 · Cited by 88
Tran, J. Q., Kovacs, S. J., McIntosh, T. S., Davis, H. M., & Martin, D. E. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/009127009903900508 · Cited by 87
Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib
Ramanathan, S., Jin, F., Sharma, S., & Kearney, B. P. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0304-0 · Cited by 85
Itoh, M., Nakajima, M., Higashi, E., Yoshida, R., Nagata, K., Yamazoe, Y., & Yokoi, T. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.107573 · Cited by 85
Weber, C., Banken, L., Birnboeck, H., & Schulz, R. (1999) · The Journal of Clinical Pharmacology · doi:10.1177/00912709922008380 · Cited by 85
An in Vitro Mechanistic Study to Elucidate the Desipramine/Bupropion Clinical Drug-Drug Interaction
Reese, M. J., Wurm, R. M., Muir, K. T., Generaux, G. T., John‐Williams, L. S., & McConn, D. J. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.020198 · Cited by 84
Clinical Pharmacokinetics of Vemurafenib
Zhang, W., Heinzmann, D., & Grippo, J. F. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0523-7 · Cited by 84
Regulation of gene expression by CAR: an update
Kobayashi, K., Hashimoto, M., Honkakoski, P., & Negishi, M. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1522-9 · Cited by 83
Post-translational modification of pregnane x receptor
Staudinger, J. L., Xu, C., Biswas, A., & Mani, S. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2011.02.011 · Cited by 83
Computational prediction of cytochrome P450 inhibition and induction
Kato, H. (2019) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2019.11.006 · Cited by 83
Dealing with the complex drug–drug interactions: Towards mechanistic models
Varma, M. V. S., Pang, K. S., Isoherranen, N., & Zhao, P. (2014) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1934 · Cited by 82
BURSTEIN, S., & KLAIBER, E. L. (1965) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-25-2-293 · Cited by 82
The Transformer database: biotransformation of xenobiotics
Hoffmann, M. F., Preissner, S. C., Preissner, S. C., Nickel, J., Dunkel, M., Preißner, S., Preißner, S., & Preißner, S. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1246 · Cited by 82
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects
Asimus, S., Elsherbiny, D. A., Hai, T. N., Jansson, B., Hướng, N. V., Petzold, M., Simonsson, U. S. H., & Ashton, M. (2007) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2007.00471.x · Cited by 81
The Influence of St. John's Wort on CYP2C19 Activity with Respect to Genotype
Wang, L., Zhu, B. Y., El‐Aty, A. M. A., Zhou, G., Li, Z., Wu, J., Chen, G., Liu, J., Tang, Z., An, W., et al. (2004) · The Journal of Clinical Pharmacology · doi:10.1177/0091270004265642 · Cited by 81
Yu, A., Tian, Y., Tu, M., Ho, P. Y., & Jilek, J. L. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067470 · Cited by 81
Tian, X., Zhang, H., Heimbach, T., He, H., Buchbinder, A., Aghoghovbia, M., & Hourcade‐Potelleret, F. (2018) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1312 · Cited by 80
Decreased Concentration of Phenacetin in Plasma of Cigarette Smokers
Pantuck, E. J., Kuntzman, R. G., & Conney, A. H. (1972) · Science · doi:10.1126/science.175.4027.1248 · Cited by 79
Real-Time Polymerase Chain Reaction Analysis of CYP1B1 Gene Expression in Human Liver
Chang, T. K. H., Chen, J., Pillay, V., Ho, J.-Y., & Bandiera, S. M. (2003) · Toxicological Sciences · doi:10.1093/toxsci/71.1.11 · Cited by 79
Lutz, J. D., Kirby, B. J., Wang, L., Song, Q., Ling, J. R., Massetto, B., Worth, A., Kearney, B. P., & Mathias, A. A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1072 · Cited by 79
Tran, J. Q., Kovacs, S. J., McIntosh, T. S., et al. (1999) · PubMed · Cited by 78
Induction of cytochrome P450 enzymes: a view on human in vivo findings
Hukkanen, J. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.39 · Cited by 78
Self-citationWilby, K. J., Greanya, E. D., Ford, J., Yoshida, E. M., & Partovi, N. (2012) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31022-1 · Cited by 78
Crauwels, H. M., van Heeswijk, R. P. G., Stevens, M., Buelens, A., Vanveggel, S., Boven, K., & Hoetelmans, R. M. W. (2013) · PubMed · Cited by 77
Funck‐Brentano, C., Becquemont, L., Leneveu, A., Roux, A., Jaillon, P., & Beaune, P. H. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36460-2 · Cited by 77
Andreasen, A., Brøsen, K., & Damkier, P. (2007) · Epilepsia · doi:10.1111/j.1528-1167.2007.00924.x · Cited by 76
Hakkola, J., Bernasconi, C., Coecke, S., Richert, L., Andersson, T. B., & Pelkonen, O. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13004 · Cited by 76
Self-citationLu, C., & Di, L. (2019) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.2212 · Cited by 76
Huuskonen, P., Storvik, M., Reinisalo, M., Honkakoski, P., Rysä, J., Hakkola, J., & Pasanen, M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100376 · Cited by 75
Self-citationPursche, S., Schleyer, E., Bonin, M. V., Ehninger, G., Said, S. M., Prondzinsky, R., Illmer, T., Wang, Y., Hosius, C., Nikolova, Z. G., et al. (2008) · Current Clinical Pharmacology · doi:10.2174/157488408785747656 · Cited by 75
Clinical Pharmacokinetics and Pharmacodynamics of Bosutinib
Abbas, R., & Hsyu, P. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0391-6 · Cited by 75
Collom, S. L., Laddusaw, R. M., Burch, A. M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m707630200 · Cited by 74
Chen, Y., Xiao, P., Ouyang, D., Fan, L., Guo, D., Wang, Y., Yang, H., Tu, J., Zhou, G., Huang, Y., et al. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05158.x · Cited by 74
Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants
Tanaka, C., Yin, O. Q. P., Smith, T., Sethuraman, V. S., Grouss, K., Galitz, L., Harrell, R. E., & SCHRAN, H. F. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010367428 · Cited by 73
Placental Markers of Human Exposure to Polychlorinated Biphenyls and Polychlorinated Dibenzofurans
Lucier, G. W., Nelson, K. G., Everson, R., Wong, T. K., Philpot, R. M., Tiernan, T. O., Taylor, M. J., & Sunahara, G. I. (1987) · Environmental Health Perspectives · doi:10.1289/ehp.877679 · Cited by 73
Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
James, A. J., Smith, C. C., Litzow, M. R., Perl, A. E., Altman, J. K., Shepard, D. R., Kadokura, T., Souda, K., Patton, M., Lu, Z., et al. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00888-w · Cited by 73
Selective Induction of Human Hepatic Cytochromes P450 2B6 and 3A4 by Metamizole
Saußele, T., Burk, O., Blievernicht, J. K., Klein, K., Nussler, A. K., Nüssler, N. C., Hengstler, J. G., Eichelbaum, M. F., Schwab, M. G., & Zanger, U. M. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100138 · Cited by 72
A current structural perspective on PXR and CAR in drug metabolism
Buchman, C. D., Chai, S. C., & Chen, T. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1476488 · Cited by 72
Cigarette smoke-induced differential gene expression in blood cells from monozygotic twin pairs
van Leeuwen, D. M., van Agen, E., Gottschalk, R. W. H., VLIETINCK, R. F., Gielen, M., van Herwijnen, M. H. M., Maas, L. M., Kleinjans, J. C. S., & van Delft, J. H. M. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl199 · Cited by 71
Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test
Parker, A. C., Pritchard, P., Preston, T., & Choonara, I. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00684.x · Cited by 70
Schellens, J. H. M., van der Wart, J. H. F., Brugman, M., et al. (1989) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23442-5 · Cited by 70
O’Shaughnessy, P. J., Monteiro, A., Bhattacharya, S., & Fowler, P. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1437 · Cited by 70
Gay, C., Toulet, D., & Corre, P. L. (2016) · Hematological Oncology · doi:10.1002/hon.2335 · Cited by 69
Reddy, V. P., Walker, M., Sharma, P. K., Ballard, P. G., & Vishwanathan, K. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12289 · Cited by 69
Krishna, G., Moton, A., Ma, L., Savant, I. A., Martinho, M., Seiberling, M., & McLeod, J. F. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.02.022 · Cited by 68
Physiologically Based Pharmacokinetic Modeling of Palbociclib
Yu, Y., Loi, C., Hoffman, J., & Wang, D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.792 · Cited by 68
Kirby, B., Collier, A. C., Kharasch, E. D., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038646 · Cited by 67
Lefebvre, J. M., Poirier, L., Poirier, P., et al. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02796.x · Cited by 66
Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin
Depré, M., Hecken, A. V., Oeyen, M., Lepeleire, I. D., Laethem, T., Rothenberg, P., Petty, K. J., Majumdar, A. K., Crumley, T. M., Panebianco, D. L., et al. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0907-8 · Cited by 65
van Giersbergen, P. L. M., Treiber, A., Clozel, M., Bodin, F., & Dingemanse, J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.122473 · Cited by 65
Johansson, S. A., Read, J., Oliver, S. D., Steinberg, M., Li, Y., Lisbon, E. A., Mathews, D. R., Leese, P. T., & Martin, P. D. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0161-2 · Cited by 65
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection
Sherman, E. M., Worley, M. V., Unger, N. R., Gauthier, T. P., & Schafer, J. J. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.07.022 · Cited by 64
CYP3A4-mediated hepatic metabolism of the HIV-1 protease inhibitor saquinavirin vitro
Eagling, V. A., WILTSHIRE, H. R., Whitcombe, I. W. A., & Back, D. J. (2002) · Xenobiotica · doi:10.1080/00498250110085845 · Cited by 64
Bernasconi, C., Pelkonen, O., Andersson, T. B., Strickland, J. A., Wilk–Zasadna, I., Asturiol, D., Cole, T., Liška, R., Worth, A. P., Müller‐Vieira, U., et al. (2019) · Toxicology in Vitro · doi:10.1016/j.tiv.2019.05.019 · Cited by 64
Self-citationEffects of ketoconazole and carbamazepine on lapatinib pharmacokinetics in healthy subjects
Smith, D. A., Koch, K. M., Arya, N., Bowen, C. J., Herendeen, J. M., & Beelen, A. P. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03370.x · Cited by 63
Rasheed, A., Hines, R. N., & McCarver-May, D. G. (1997) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1997.8152 · Cited by 63
Backman, J. T., Granfors, M. T., & Neuvonen, P. J. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0127-x · Cited by 63
Penzak, S. R., Robertson, S. M. C., Hunt, J. D., Chairez, C. L., Malati, C. Y., Alfaro, R. M., Stevenson, J. M., & Kovacs, J. A. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.8.797 · Cited by 62
Effects of Ketoconazole on the Pharmacokinetics of Ponatinib in Healthy Subjects
Narasimhan, N. I., Dorer, D. J., Niland, K., Haluska, F. G., & Sonnichsen, D. S. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.109 · Cited by 61
Activity of CYP2E1 and CYP3A enzymes in adults with moderate alcohol consumption
Liangpunsakul, S., Kolwankar, D., Pinto, A. G., Gorski, J. C., Hall, S. D., & Chalasani, N. (2005) · Hepatology · doi:10.1002/hep.20673 · Cited by 61
Dumond, J. B., Vourvahis, M., Rezk, N. L., Patterson, K. B., Tien, H.-C., White, N., Jennings, S. H., Choi, S. O., Li, J., Wagner, M. J., et al. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.253 · Cited by 61
Lämsä, V., Levonen, A., Leinonen, H. M., Ylä‐Herttuala, S., Yamamoto, M. P., & Hakkola, J. (2010) · Chemical Research in Toxicology · doi:10.1021/tx100084c · Cited by 60
Self-citationRole and modulation of drug transporters in HIV-1 therapy
Alam, C., Whyte-Allman, S.-K., Omeragic, A., & Bendayan, R. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.001 · Cited by 60
Role of Cytochrome P450 Enzymes in the Metabolic Activation of Tyrosine Kinase Inhibitors
Jackson, K. D., Durandis, R., & Vergne, M. J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082367 · Cited by 60
Satarug, S., Ujjin, P., Vanavanitkun, Y., Nishijo, M., Baker, J. R., & Moore, M. R. (2004) · Toxicology · doi:10.1016/j.tox.2004.06.022 · Cited by 59
Metabolic Intermediate Complex Formation of Human Cytochrome P450 3A4 by Lapatinib
Takakusa, H., Wahlin, M. D., Zhao, C., Hanson, K. L., New, L. S., Chan, E. C. Y., & Nelson, S. D. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037531 · Cited by 59
ROLE OF GLUCOCORTICOID RECEPTOR AND CONSTITUTIVE ANDROSTANE RECEPTOR
Gerbal‐Chaloin, S., Daujat‐Chavanieu, M., Pascussi, J., Pichard‐Garcia, L., Vilarem, M., & Maurel, P. (2002) · Cited by 59
An integrated pharmacokinetics ontology and corpus for text mining
Wu, H., Karnik, S., Subhadarshini, A., Wang, Z. P., Philips, S., Han, X., Chiang, C., Liu, L., Boustani, M. A., Rocha, L. M., et al. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-35 · Cited by 58
Genetic epidemiology of induced CYP3A4 activity
Rahmioğlu, N., Heaton, J. C., Clement, G., et al. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283498ecf · Cited by 58
Dirix, L. Y., Swaisland, H., Verheul, H. M. W., Rottey, S., Leunen, K., Jérusalem, G., Rolfo, C. D., Nielsen, D. L., Molife, L. R., Kristeleit, R. S., et al. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.08.010 · Cited by 58
Sorf, A., Hofman, J., Kučera, R., Štaud, F., & Čečková, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.04.013 · Cited by 58
Posada, M. M., Morse, B. L., Turner, P. K., Kulanthaivel, P., Hall, S. D., & Dickinson, G. L. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1584 · Cited by 58
Lawrence, S. K., Nguyen, D. N. P., Bowen, C., Richards‐Peterson, L. E., & Skordos, K. W. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.057778 · Cited by 57
Regulation of the Cyp2a5 Gene Involves an Aryl Hydrocarbon Receptor-Dependent Pathway
Arpiainen, S., Raffalli‐Mathieu, F., Lang, M. A., Pelkonen, O., & Hakkola, J. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.008078 · Cited by 57
Self-citationEffect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers
Robertson, P., Hellriegel, E., Arora, S., & Nelson, M. T. (2002) · Clinical pharmacology and therapy · doi:10.1067/mcp.2002.121217 · Cited by 57
Chu, X., Cai, X., Cui, D., Tang, C., Ghosal, A., Chan, G. H., Green, M. D., Kuo, Y., Liang, Y., Maciolek, C. M., et al. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.049668 · Cited by 57
Abel, S., Davis, J. D., Ridgway, C. E., Hamlin, J., & Vourvahis, M. (2008) · Antiviral Therapy · doi:10.3851/imp1297 · Cited by 57
Asaumi, R., Toshimoto, K., Tobe, Y., Hashizume, K., Nunoya, K., Imawaka, H., Lee, W., & Sugiyama, Y. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12275 · Cited by 57
Durán, I., Carles, J., Bulat, I., Hellemans, P., Mitselos, A., Ward, P., Jiao, J. J., Armas, D. R., & Chien, C. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00882-2 · Cited by 57
Extent of Urinary Excretion of p-Hydroxyphenytoin in Healthy Subjects Given Phenytoin
DICKINSON, R. G., Hooper, W. D., Patterson, M. C., et al. (1985) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198507030-00008 · Cited by 55
Function and Regulation of the Cyp2a5/CYP2A6 Genes in Response to Toxic Insults in the Liver
Abu-Bakar, A., Hakkola, J., Juvonen, R. O., Rahnasto‐Rilla, M., Raunio, H., & Lang, M. A. (2012) · Current Drug Metabolism · doi:10.2174/138920013804545223 · Cited by 55
Self-citationSchwartzberg, L. S., Yardley, D. A., ELIAS, A. D., Patel, M. R., LoRusso, P. M., Burris, H. A., Gucalp, A., Peterson, A., Blaney, M. E., Steinberg, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2339 · Cited by 55
Jeong, S., Woo, M. M., Flockhart, D. A., & Desta, Z. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-0935-7 · Cited by 54
Hamilton, M., Wolf, J. L., Drolet, D. W., Fettner, S. H., Rakhit, A. K., Witt, K., & Lum, B. L. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2390-3 · Cited by 54
Sugiyama, M., Fujita, K., Murayama, N., Akiyama, Y., Yamazaki, H., & Sasaki, Y. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.037853 · Cited by 54
Barecki-Roach, M., Casciano, C. N., Johnson, W. W., & Clement, R. P. (2001) · PubMed · Cited by 54
Morcos, P. N., Cleary, Y., Guerini, E., Dall, G., Bogman, K., Petris, L. D., Viteri, S., Bordogna, W., Yu, L. J., Martin‐Facklam, M., et al. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.298 · Cited by 54
Feng, H., Huang, S., Wang, W., & Zhou, H. (1998) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1998.00643.x · Cited by 53
Regulation of CYP2A5 Gene by the Transcription Factor Nuclear Factor (Erythroid-Derived 2)-Like 2
Abu-Bakar, A., Lämsä, V., Arpiainen, S., Moore, M. R., Lang, M. A., & Hakkola, J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014423 · Cited by 53
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Etravirine: An Updated Review
Havens, J. P., Podany, A. T., Scarsi, K. K., & Fletcher, C. V. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00830-9 · Cited by 53
Clinical Pharmacology of Deferasirox
Tanaka, C. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0151-4 · Cited by 52
Fan, L., Wang, J., Jiang, F., et al. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0594-3 · Cited by 52
Baker, J. R., Satarug, S., Reilly, P. E. B., et al. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00716-x · Cited by 52
Dingemanse, J., Schaarschmidt, D., & van Giersbergen, P. L. M. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342030-00004 · Cited by 51
Horn, E. P., Tucker, M. A., Lambert, G. H., Silverman, D. T., Zametkin, D. P., Sinha, R. R., Hartge, T., Landi, M. T., & Caporaso, N. E. (1995) · PubMed · Cited by 51
Retinoids activate RXR/CAR-mediated pathway and induce CYP3A
Chen, S., Wang, K., & Wan, Y. Y. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.08.012 · Cited by 50
Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism
Wietholtz, H., Zysset, T., Kreiten, K., Kohl, D., B�chsel, R., & Matern, S. (1989) · European Journal of Clinical Pharmacology · doi:10.1007/bf00558303 · Cited by 50
Yu, J., Ritchie, T. K., Mulgaonkar, A., & Ragueneau, I. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.060392 · Cited by 50
Takusagawa, S., Miyashita, A., Iwatsubo, T., & Usui, T. (2012) · Xenobiotica · doi:10.3109/00498254.2012.700140 · Cited by 49
Expression and induction of CYP3As in human fetal hepatocytes
Matsunaga, T., Maruyama, M., Harada, E., Katsuyama, Y., Sugihara, N., Ise, H., Negishi, N., Ikeda, U., & Ohmori, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.04.041 · Cited by 49
Influence of Ritonavir on Olanzapine Pharmacokinetics in Healthy Volunteers
Penzak, S. R., Hon, Y. Y., Lawhorn, W. D., Shirley, K. L., Spratlin, V. E., & Jann, M. W. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200208000-00006 · Cited by 49
Ethanol Increases Content and Activity of Human Cytochrome P4502E1 in a Transduced HepG2 Cell Line
Carroccio, A., Wu, D., & Cederbaum, A. I. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.2242 · Cited by 49
Suttle, A. B., Grossmann, K. F., Ouellet, D., Richards‐Peterson, L. E., Aktan, G., Gordon, M. S., LoRusso, P. M., Infante, J. R., Sharma, S., Kendra, K. L., et al. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.437 · Cited by 49
Smith, G. C., Ibbotson, S. H., Comrie, M., Dawe, R. S., Bryden, A., Ferguson, J., & Wolf, C. R. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07317.x · Cited by 48
Michaud, V., Ogburn, E. T., Thong, N., Aregbe, A. O., Quigg, T. C., Flockhart, D. A., & Desta, Z. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.249 · Cited by 47
Bapiro, T. E., Sayi, J., Hasler, J. A., Jande, M. B., Rimoy, G., Masselle, A., & Masimirembwa, C. M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0037-3 · Cited by 47
Pasanen, M., Haaparanta, T., Sundin, M., Sivonen, P., Vakakangas, K., Raunio, H., Hines, R. N., Gustafsson, J.-Å., & Pelkonen, O. (1990) · Toxicology · doi:10.1016/0300-483x(90)90108-s · Cited by 47
Self-citationKarjalainen, M. J., Neuvonen, P. J., & Backman, J. T. (2008) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2008.00252.x · Cited by 47
Abu-Bakar, A. (2004) · Toxicology Letters · doi:10.1016/j.toxlet.2003.10.029 · Cited by 47
Sager, J. E., Tripathy, S., Price, L., Nath, A., Chang, J. S., Stephenson‐Famy, A., & Isoherranen, N. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.11.007 · Cited by 47
Lambert, G. H., Schoeller, D. A., Humphrey, H. E. B., et al. (1990) · Environmental Health Perspectives · doi:10.1289/ehp.9089175 · Cited by 46
Dailly, É., Tribut, O., Tattevin, P., Arvieux, C., Perré, P., Raffi, F., & Jolliet, P. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0122-2 · Cited by 45
Berlin, I., Gasior, M., & Moolchan, E. T. (2007) · Nicotine & Tobacco Research · doi:10.1080/14622200701243193 · Cited by 45
Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity
Ernstgård, L., Warholm, M., & Johanson, G. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2004.02132.x · Cited by 44
Genome-Wide Discovery of Drug-Dependent Human Liver Regulatory Elements
Smith, R. P., Eckalbar, W., Morrissey, K., Luizon, M., Hoffmann, T., Sun, X.-F., Jones, S. L., Aldred, S. F., Ramamoorthy, A., Desta, Z., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004648 · Cited by 44
Yamazaki, T., Desai, A. V., Goldwater, R., Han, D., Howieson, C., Akhtar, S., Kowalski, D. L., Lademacher, C., Pearlman, H., Rammelsberg, D., et al. (2016) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.281 · Cited by 44
Regulation of PXR and CAR by protein-protein interaction and signaling crosstalk
Oladimeji, P. O., Cui, H., Zhang, C., & Chen, T. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2016.1201069 · Cited by 44
Yu, J., Zhou, Z., Owens, K. H., Ritchie, T. K., & Ragueneau, I. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.073411 · Cited by 44
Occupational Toluene Exposure Induces Cytochrome P450 2E1 mRNA Expression in Peripheral Lymphocytes
Mendoza‐Cantú, A., Castorena‐Torres, F., de León, M. B., Cisneros, B., López‐Carrillo, L., Rojas‐García, A. E., Aguilar-Salinas, A., Manno, M., & Albores, A. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.8192 · Cited by 43
Parmentier, Y., Pothier, C., Delmas, A., Caradec, F., Trancart, M.-M., Guillet, F., Bouaita, B., Chesné, C., Houston, J. B., & Walther, B. (2016) · Xenobiotica · doi:10.1080/00498254.2016.1208854 · Cited by 43
The Role of Retinoid X Receptor α in Regulating Alcohol Metabolism
Gyamfi, M. A., Kocsis, M. G., He, L., Dai, G., Mendy, A. J., & Wan, Y. Y. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.108175 · Cited by 42
Interaction of Lapatinib with Cytochrome P450 3A5
Chan, E. C. Y., New, L. S., Chua, T. B., Yap, C. W., Ho, H. K., & Nelson, S. D. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.044958 · Cited by 42
Absolute Bioavailability of Osimertinib in Healthy Adults
Vishwanathan, K., So, K., Thomas, K., Bramley, A., English, S., & Collier, J. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.467 · Cited by 42
Chhun, S., Verstuyft, C., Rizzo‐Padoin, N., Simoneau, G., Becquemont, L., Idy-Peretti, I., Swaisland, A. J., Wortelboer, R., Bergmann, J., & Mouly, S. J. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03438.x · Cited by 40
Mechanism-Based Inactivation of Human CYP2E1 by Diethyldithocarbamate
Pratt–Hyatt, M., Lin, H.-L., & Hollenberg, P. F. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034710 · Cited by 40
Effect of danshen extract on the activity of CYP3A4 in healthy volunteers
Qiu, F., Wang, G., Zhang, R., Sun, J., Jiang, J. C., & Ma, Y. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03624.x · Cited by 39
Skerjanec, A., Wang, J., Maren, K., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009340418 · Cited by 39
Chien, J. Y., Peter, R. M., Nolan, C. M., Wartell, C., Slattery, J. T., Nelson, S. D., Carithers, R. L., & Thummel, K. E. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90179-x · Cited by 39
Drug interactions of meglitinide antidiabetics involving CYP enzymes and OATP1B1 transporter
Maideen, N. M. P., Gobinath, M., & Balasubramanian, K. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818767220 · Cited by 39
Britz, H., Hanke, N., Volz, A., Spigset, O., Schwab, M. G., Eißing, T., Wendl, T., Frechen, S., & Lehr, T. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12397 · Cited by 39
Budha, N. R., Ji, T., Musib, L. C., Eppler, S., Dresser, M. J., Chen, Y., & Jin, J. Y. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0412-5 · Cited by 38
Gupta, N., Hanley, M. J., Venkatakrishnan, K., Bessudo, A., Rasco, D. W., Sharma, S., O’Neil, B. H., Wang, B., Liu, G., Ke, A. B., et al. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.988 · Cited by 38
Lin, D., Kostov, R. V., Huang, J. T.-J., Henderson, C. J., & Wolf, C. R. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.243246 · Cited by 38
Niu, B., Coslo, D. M., Bataille, A. R., Albert, I., Pugh, B. F., & Omiecinski, C. J. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky692 · Cited by 37
Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2
Yokota, S., Higashi, E., Fukami, T., Yokoi, T., & Nakajima, M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.09.020 · Cited by 37
Theophylline‐rifampicin interaction: non‐selective induction of theophylline metabolic pathways.
Robson, R., Miners, J. O., Wing, L., & Birkett, D. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02487.x · Cited by 37
Yu, J., Ritchie, T. K., Zhou, Z., & Ragueneau, I. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.066720 · Cited by 37
Hutzler, J. M., Balogh, L. M., Zientek, M. A., Kumar, V., & Tracy, T. S. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.023358 · Cited by 36
Lecamwasam, D., Franklin, C. S., & Turner, P. (1975) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1975.tb01584.x · Cited by 36
Improved Predictions of Drug–Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A
Yadav, J., Korzekwa, K., & Nagar, S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00129 · Cited by 36
Sinués, B., Fanlo, A., Mayayo, E., Carcas, C., Vicente-Romero, J., Arenaz, I., & Cebollada, A. (2008) · Human & Experimental Toxicology · doi:10.1177/0960327107082224 · Cited by 35
Inactivation of Human Cytochrome P450 3A4 and 3A5 by Dronedarone and N-Desbutyl Dronedarone
Hong, Y., Chia, Y. M. F., Yeo, R. H., Venkatesan, G., Koh, S. K., Chai, C. L. L., Zhou, L., Kojodjojo, P., & Chan, E. C. Y. (2015) · Molecular Pharmacology · doi:10.1124/mol.115.100891 · Cited by 35
McCormick, A., Swaisland, H., Reddy, V. P., Learoyd, M., & Scarfe, G. B. (2017) · Xenobiotica · doi:10.1080/00498254.2017.1346332 · Cited by 35
Cleary, Y., Gertz, M., Morcos, P. N., Yu, L. J., Youdim, K. A., Phipps, A., Fowler, S. M., & Parrott, N. J. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.956 · Cited by 35
Cotinine in Human Placenta Predicts Induction of Gene Expression in Fetal Tissues
Vyhlidal, C. A., Riffel, A. K., Haley, K. J., Sharma, S., Dai, H. D., Tantisira, K. G., Weiss, S. T., & Leeder, J. S. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.049999 · Cited by 34
PCB Exposure and in Vivo CYP1A2 Activity among Native Americans
Fitzgerald, E. F., Hwang, S., Lambert, G. H., Gómez, M. I., & Tarbell, A. M. (2004) · Environmental Health Perspectives · doi:10.1289/ehp.7370 · Cited by 34
Paine, M. F., Shen, D. D., & McCune, J. S. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079962 · Cited by 34
Akiyoshi, T., Ito, M., Murase, S., Miyazaki, M., Guengerich, F. P., Nakamura, K., Yamamoto, K., & Ohtani, H. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rg-134 · Cited by 33
Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
Mihara, K., Svensson, U. S. H., Tybring, G., Hai, T. N., Bertilsson, L., & Ashton, M. (1999) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1999.tb00379.x · Cited by 33
The influence of rifampin treatment on caffeine clearance in healthy man
Wietholtz, H., Zysset, T., Marschall, H., Generet, K., & Matern, S. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80263-0 · Cited by 33
Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174*
Goldberg, M. R., Lo, M. W., Deutsch, P., Wilson, S. E., McWilliams, E. J., & McCrea, J. B. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)80004-x · Cited by 33
Interaction of secobarbital with warfarin pseudoracemates
O’Reilly, R. A., Trager, W. F., Motley, C. H., & Howald, W. N. (1980) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1980.149 · Cited by 33
Chen, J., Xu, H., Pawlak, S., James, L. P., Peltz, G., Lee, K., Ginman, K., Bergeron, M., & Pithavala, Y. K. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01198-9 · Cited by 33
Moreland, T., Park, B. K., & Rylance, G. (1982) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1982.tb02050.x · Cited by 32
Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions
Khalilieh, S. G., Yee, K. L., Sánchez, R. I., Li, F., Anderson, M. S., Sura, M., Laethem, T., Rasmussen, S., Bortel, L. M. V., Lancker, G. V., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02016-18 · Cited by 32
Adedoyin, A. B., Stiff, D. D., Smith, D. C., Romkes, M., Bahnson, R., Day, R., Hofacker, J., Branch, R. A., & Trump, D. L. (1997) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800050719 · Cited by 31
Evidence of an interaction between nifedipine and nafcillin in humans
Lang, C. C., Jamal, S. K., Mohamed, Z., Mustafa, M. R., Mohd, M. A., & Lee, T. C. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01789.x · Cited by 30
Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo
Villikka, K., Varis, T., Backman, J. T., et al. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s002280100340 · Cited by 30
A SUMO-acetyl switch in PXR biology
Cui, W., Sun, M., Zhang, S., Shen, X., Galeva, N. A., Williams, T. D., & Staudinger, J. L. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.02.008 · Cited by 30
Tugnait, M., Gupta, N., Hanley, M. J., Sonnichsen, D. S., Kerstein, D., Dorer, D. J., Venkatakrishnan, K., & Narasimhan, N. I. (2019) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.723 · Cited by 30
Estimated Flavonoid Intake of the Elderly in the United States and Around the World
Chun, O. K., Lee, S. G., Wang, Y., Vance, T. M., & Song, W. O. (2012) · Journal of Nutrition in Gerontology and Geriatrics · doi:10.1080/21551197.2012.702530 · Cited by 29
Polychlorinated biphenyl (PCB) induction of CYP3A4 enzyme activity in healthy Faroese adults
Petersen, M. S., Halling, J., Damkier, P., et al. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.07.002 · Cited by 29
Zang, M., Zhu, F., Li, X., Yang, A., & Xing, J. (2014) · Malaria Journal · doi:10.1186/1475-2875-13-214 · Cited by 29
Qiu, F., Jiang, J. C., Ma, Y., Wang, G., Gao, C., Zhang, X., Zhang, L., Liu, S., He, M., Zhu, L., et al. (2013) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2013/730734 · Cited by 29
Dörrenhaus, A., Müller, T., & Roos, P. H. (2006) · Archives of Toxicology · doi:10.1007/s00204-006-0134-9 · Cited by 28
Interaction Between Warfarin and Nafcillin: Case Report and Review of the Literature
Kim, K. Y., Frey, R., Epplen, K. T., & Foruhari, F. (2007) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.10.1467 · Cited by 28
Effects of rifampicin on global gene expression in human small intestine
Oscarson, M., Burk, O., Winter, S., Schwab, M. G., Wolbold, R., Dippon, J., Eichelbaum, M. F., & Meyer, U. (2007) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3280143dfc · Cited by 27
Lei, H., Yu, X., Xie, H., Li, H., Fan, L., Dai, L.-L., Chen, Y., & Zhou, H. (2010) · Xenobiotica · doi:10.3109/00498250903509383 · Cited by 27
Characterization of a Human Keratinocyte HaCaT Cell Line Model to Study the Regulation of CYP2S1
McNeilly, A. D., Woods, J. A., Ibbotson, S. H., Wolf, C. R., & Smith, G. C. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042085 · Cited by 27
Marzolini, C., Rajoli, R. K. R., Battegay, M., Elzi, L., Back, D. J., & Siccardi, M. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0447-7 · Cited by 27
Chetty, M., Miller, R., & Seymour, M. A. (1998) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199802000-00011 · Cited by 26
Coulet, M., Dacasto, M., Eeckhoutte, C., Larrieu, G., Sutra, J. F., Alvinerie, M., Macé, K., Pfeifer, A., & Galtier, P. (1998) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.1998.tb00946.x · Cited by 26
Wang, Y., Sparidans, R. W., Li, W., Lebre, M. C., Beijnen, J. H., & Schinkel, A. H. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15034 · Cited by 26
Filppula, A. M., Parvizi, R., Mateus, A., Baranczewski, P., & Artursson, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-42051-x · Cited by 25
Malhi, V., Colburn, D. E., Williams, S. J. A., Hop, C. E. C. A., Dresser, M. J., Chandra, P., & Graham, R. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3020-z · Cited by 24
Zhao, B., Zhang, W., Yu, D., Xu, J., & Wei, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.011 · Cited by 24
Hofman, J., Sorf, A., Vagiannis, D., Sucha, S., Novotná, E., Kammerer, S., Küpper, J., Čečková, M., & Štaud, F. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.119.086975 · Cited by 24
Du, Q., Wang, Z., He, L., Jiang, X., & Wang, L. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1552-2 · Cited by 23
In vitro-to-in vivopredictions of drug–drug interactions involving multiple reversible inhibitors
Lutz, J. D., & Isoherranen, N. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.667801 · Cited by 23
Abbas, R., Leister, C. A., Gaaloul, M. E., Chalon, S., & Sonnichsen, D. S. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.07.006 · Cited by 23
Induction of CYP3A4 by Vinblastine: Role of the Nuclear Receptor NR1I2
Smith, N. F., Mani, S., Schuetz, E. G., Yasuda, K., Sissung, T. M., Bates, S. E., Figg, W. D., & Sparreboom, A. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1p354 · Cited by 23
Cited by
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Zhao, M., Ma, J., Li, M., Zhang, Y., Jiang, B., Zhao, X., Huai, C., Shen, L., Zhang, N., He, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312808 · Cited by 1,070
Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01469-6 · Cited by 508
Therapeutic advances of targeting receptor tyrosine kinases in cancer
Tomuleasa, C., Tigu, A.-B., Munteanu, R., Moldovan, C.-S., Kegyes, D., Onaciu, A., Gulei, D., Ghiaur, G., Einsele, H., & Croce, C. M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01899-w · Cited by 260
Rani, J., Dhull, S. B., Rose, P. K., & Kidwai, M. K. (2024) · Phytomedicine · doi:10.1016/j.phymed.2023.155142 · Cited by 91
Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer
Barnett, B. S., & Greer, G. R. (2021) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2020.12.011 · Cited by 13
Metadata
- Authors
- Hakkola, J., Hukkanen, J., Turpeinen, M., & Pelkonen, O.
- Venue
- Archives of Toxicology
- Published
- 2020-10-27
- Volume
- 94
- Issue
- 11
- Pages
- 3671-3722
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- OpenAlex
- W3095525985
- Cited by
- 418
- References
- 431
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.